AI MARKET SCANNING

Aldeyra Therapeutics, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +0.10%
MAX GAP RECORD -5.93%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ALDX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 06, 2026 Earnings Release 2026-08-06 (AFTER CLOSE)
-1.89%
May 07, 2026 Earnings Release 2026-05-07 (AFTER CLOSE)
-1.73%
Feb 27, 2026 Earnings Release 2026-02-27 (AFTER CLOSE)
-1.10%
Nov 05, 2025 Earnings Release 2025-11-05 (AFTER CLOSE)
+0.20%
Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE)
-0.19%
May 14, 2025 Earnings Release 2025-05-14 (AFTER CLOSE)
+0.92%
Feb 28, 2025 Earnings Release 2025-02-28 (AFTER CLOSE)
+2.54%
Nov 07, 2024 Earnings Release 2024-11-07 (AFTER CLOSE)
+0.56%

VOLATILITY & GAP BIAS

AVG GAP MOVE 1.8%
Bullish Gaps (4)
Bearish Gaps (5)
Neutral / Flat (6)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ALDX

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗